{"id":179601,"date":"2026-02-05T03:17:34","date_gmt":"2026-02-05T08:17:34","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=179601"},"modified":"2026-02-05T03:17:37","modified_gmt":"2026-02-05T08:17:37","slug":"emcure-pharmaceuticals-q3-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/emcure-pharmaceuticals-q3-fy26-earnings-results\/","title":{"rendered":"Emcure Pharmaceuticals Q3 FY26 Earnings Results"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Executive Summary<\/strong><\/h2>\n\n\n\n<p>Emcure Pharmaceuticals Ltd reported Q3FY26 revenues of \u20b92,363 crore, up 20.38% YoY, with consolidated net profit surging 48.08% to \u20b9231 crore despite \u20b938 crore one-time labour code expenses. International sales exceeded 50% revenue mix with 24.5% growth, complemented by strong domestic chronic therapy performance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Revenue &amp; Growth<\/strong><\/h2>\n\n\n\n<p>Revenues expanded to \u20b92,363 crore from \u20b91,963 crore YoY, driven by 24.5% international growth (\u20b91,338 crore) across Europe (+29.6%), Rest of World (+30.7%), and Canada (+12.8%). Domestic sales rose 15.4% to \u20b91,025 crore led by cardio-diabetic therapies and Poviztra semaglutide launch.<\/p>\n\n\n\n<p><strong>Profitability &amp; Margins<\/strong><br>Consolidated net profit jumped 48% YoY to \u20b9231 crore from \u20b9156 crore, with EBITDA up 27.2% to \u20b9460 crore at 19.5% margins (+103 bps YoY). Basic EPS increased 49.94% to \u20b912.16 from \u20b98.11 despite exceptional labour code provisions.<\/p>\n\n\n\n<p><strong>Balance-Sheet Highlights<\/strong><br>The dataset lacks detailed balance sheet items such as assets, liabilities, equity, net debt, or current ratio for Q3FY26.<\/p>\n\n\n\n<p><strong>Cash Flow \/ Liquidity<\/strong><br>Operating cash flow, free cash flow, and liquidity metrics are not specified in the Q3FY26 dataset.<\/p>\n\n\n\n<p><strong>Key Ratios \/ Metrics<\/strong><br>International business now constitutes 57% revenue mix; Europe benefited from Manx acquisition and Amphotericin B launches. Domestic weight management entry via Novo Nordisk partnership positions Emcure for obesity segment growth amid patent expiry dynamics.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"839\" height=\"1024\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E-839x1024.png\" alt=\"\" class=\"wp-image-179602\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E.png 1489w\" sizes=\"auto, (max-width: 839px) 100vw, 839px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Executive Summary Emcure Pharmaceuticals Ltd reported Q3FY26 revenues of \u20b92,363 crore, up 20.38% YoY, with consolidated net profit surging 48.08% to \u20b9231 crore despite \u20b938 crore one-time labour code expenses. International sales exceeded 50% revenue mix with 24.5% growth, complemented by strong domestic chronic therapy performance. Revenue &amp; Growth Revenues expanded to \u20b92,363 crore from [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":179602,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-179601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/E.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":171315,"url":"https:\/\/alphastreet.com\/india\/emcure-q1-fy26-earnings-results-2\/","url_meta":{"origin":179601,"position":0},"title":"Emcure Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 17, 2025","format":false,"excerpt":"Company Overview: Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally, serving diverse therapeutic segments. Presenting below its Q1 FY26 Earnings Results. Financial Highlights for Q1 FY26: Revenue: \u20b92,101 crore, up 15.76% year-on-year from \u20b91,815 crore Total Expenses: \u20b91,810 crore, up 10.91% year-on-year from \u20b91,632 crore Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"EMCURE Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/EMC.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172833,"url":"https:\/\/alphastreet.com\/india\/emcure-q2-fy26-earnings-results\/","url_meta":{"origin":179601,"position":1},"title":"Emcure Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 1, 2025","format":false,"excerpt":"Emcure Pharmaceuticals Ltd , incorporated in 1981 and a global manufacturer and marketer of pharmaceutical products, reported strong financial results for Q2FY26. Financial Highlights: Revenues increased 13.39% year-on-year to \u20b92,270 crore from \u20b92,002 crore. Total expenses rose 9.52% to \u20b91,932 crore from \u20b91,764 crore. Consolidated net profit grew 24.26% to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169930,"url":"https:\/\/alphastreet.com\/india\/alembic-pharmaceuticals-q1-fy26-earnings-results-revenue-up-10-net-profit-rises-14-yoy\/","url_meta":{"origin":179601,"position":2},"title":"Alembic Pharmaceuticals Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 8, 2025","format":false,"excerpt":"Alembic Pharmaceuticals Limited is a leading player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates 3 R&D centers and 5 advanced manufacturing facilities, supporting global exports and a robust domestic presence. Presenting below are its Q1 FY26\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"APLLTD Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169824,"url":"https:\/\/alphastreet.com\/india\/j-b-chemicals-pharmaceuticals-ltd-q1-fy26-earnings-results-revenue-up-9-net-profit-rises-14-yoy\/","url_meta":{"origin":179601,"position":3},"title":"J B Chemicals &#038; Pharmaceuticals Ltd Q1 FY26 Earnings Results \u2013 Revenue Up 9%, Net Profit Rises 14% YoY","author":"Divyansh_Kasana","date":"August 6, 2025","format":false,"excerpt":"J.B. Chemicals and Pharmaceuticals Limited (JBCPL), established in 1976, stands as one of India\u2019s prominent pharmaceutical firms with a strong integrated presence in both domestic and global markets. Renowned for its commitment to affordable, high-quality medicines, JBCPL continues to build trust among healthcare professionals and patients across geographies. Q1 FY26\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/JBCHE.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169071,"url":"https:\/\/alphastreet.com\/india\/emcure-pharmaceuticals-ltd-q4fy25-63-rise-in-profits\/","url_meta":{"origin":179601,"position":4},"title":"Emcure Pharmaceuticals Ltd Q4FY25; 63% rise in Profits","author":"Divyansh_Kasana","date":"July 9, 2025","format":false,"excerpt":"Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally Financial Results: Emcure Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b92,116.00 Crores up from \u20b91,771.00 Crore year on year, a rise of 19.48%. Total Expenses for Q4FY25 of \u20b91,850.00 Crores up from \u20b91,616.00 Crores year on year, a\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/I-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":178988,"url":"https:\/\/alphastreet.com\/india\/birla-corporation-q3-fy26-earnings-results\/","url_meta":{"origin":179601,"position":5},"title":"Birla Corporation Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"February 2, 2026","format":false,"excerpt":"Executive Summary Birla Corporation Ltd reported Q3FY26 revenues of \u20b92,159 crore, down 4.34% YoY, but consolidated net profit surged 70.97% to \u20b953 crore through 7.49% expense cuts and cost optimization. Cement demand recovered in December led by B2B sales, boosting margins despite seasonal weakness. Revenue & Growth Revenues declined to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/BIRLA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/BIRLA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/BIRLA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/BIRLA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/BIRLA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/BIRLA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179601"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179601\/revisions"}],"predecessor-version":[{"id":179603,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179601\/revisions\/179603"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/179602"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}